ATRT-SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance
- PMID: 35501487
- PMCID: PMC9107423
- DOI: 10.1007/s00401-022-02424-5
ATRT-SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance
Abstract
Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive central nervous system tumor characterized by loss of SMARCB1/INI1 protein expression and comprises three distinct molecular groups, ATRT-TYR, ATRT-MYC and ATRT-SHH. ATRT-SHH represents the largest molecular group and is heterogeneous with regard to age, tumor location and epigenetic profile. We, therefore, aimed to investigate if heterogeneity within ATRT-SHH might also have biological and clinical importance. Consensus clustering of DNA methylation profiles and confirmatory t-SNE analysis of 65 ATRT-SHH yielded three robust molecular subgroups, i.e., SHH-1A, SHH-1B and SHH-2. These subgroups differed by median age of onset (SHH-1A: 18 months, SHH-1B: 107 months, SHH-2: 13 months) and tumor location (SHH-1A: 88% supratentorial; SHH-1B: 85% supratentorial; SHH-2: 93% infratentorial, often extending to the pineal region). Subgroups showed comparable SMARCB1 mutational profiles, but pathogenic/likely pathogenic SMARCB1 germline variants were over-represented in SHH-2 (63%) as compared to SHH-1A (20%) and SHH-1B (0%). Protein expression of proneural marker ASCL1 (enriched in SHH-1B) and glial markers OLIG2 and GFAP (absent in SHH-2) as well as global mRNA expression patterns differed, but all subgroups were characterized by overexpression of SHH as well as Notch pathway members. In a Drosophila model, knockdown of Snr1 (the fly homologue of SMARCB1) in hedgehog activated cells not only altered hedgehog signaling, but also caused aberrant Notch signaling and formation of tumor-like structures. Finally, on survival analysis, molecular subgroup and age of onset (but not ASCL1 staining status) were independently associated with overall survival, older patients (> 3 years) harboring SHH-1B experiencing relatively favorable outcome. In conclusion, ATRT-SHH comprises three subgroups characterized by SHH and Notch pathway activation, but divergent molecular and clinical features. Our data suggest that molecular subgrouping of ATRT-SHH has prognostic relevance and might aid to stratify patients within future clinical trials.
Keywords: ASCL1; Atypical teratoid/rhabdoid tumor; DNA methylation profiling; GFAP; Gene expression; Neuroradiology; OLIG2; Overall survival; Prognosis; Sonic hedgehog.
© 2022. The Author(s).
Conflict of interest statement
The authors have no conflict of interest to declare.
Figures







Similar articles
-
Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome.Brain Pathol. 2017 Jul;27(4):411-418. doi: 10.1111/bpa.12413. Epub 2016 Aug 11. Brain Pathol. 2017. PMID: 27380723 Free PMC article.
-
Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.Acta Neuropathol. 2021 Feb;141(2):291-301. doi: 10.1007/s00401-020-02250-7. Epub 2020 Dec 17. Acta Neuropathol. 2021. PMID: 33331994 Free PMC article.
-
Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup.Brain Pathol. 2021 Sep;31(5):e12967. doi: 10.1111/bpa.12967. Epub 2021 May 3. Brain Pathol. 2021. PMID: 33938067 Free PMC article.
-
Atypical Teratoid/Rhabdoid Sellar Tumor in an Adult with a Familial History of a Germline SMARCB1 Mutation: Case Report and Review of the Literature.World Neurosurg. 2019 Jul;127:336-345. doi: 10.1016/j.wneu.2019.04.083. Epub 2019 Apr 17. World Neurosurg. 2019. PMID: 31004861 Review.
-
Current Molecular and Clinical Landscape of ATRT - The Link to Future Therapies.Cancer Manag Res. 2023 Dec 7;15:1369-1393. doi: 10.2147/CMAR.S379451. eCollection 2023. Cancer Manag Res. 2023. PMID: 38089834 Free PMC article. Review.
Cited by
-
Development and epigenetic regulation of Atypical teratoid/rhabdoid tumors in the context of cell-of-origin and halted cell differentiation.Neurooncol Adv. 2024 Sep 23;6(1):vdae162. doi: 10.1093/noajnl/vdae162. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39465218 Free PMC article. Review.
-
Atypical Teratoid/Rhabdoid Tumor with Retained SMARCB1 (INI1) Expression and Rare SMARCA4 Gene Mutation: A Case Report of a Pediatric Patient.Reports (MDPI). 2024 Apr 22;7(2):28. doi: 10.3390/reports7020028. Reports (MDPI). 2024. PMID: 40729139 Free PMC article.
-
Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors.Cell Rep Med. 2024 Sep 17;5(9):101700. doi: 10.1016/j.xcrm.2024.101700. Epub 2024 Aug 28. Cell Rep Med. 2024. PMID: 39208799 Free PMC article.
-
Clinical characteristics of patients with atypical teratoid/rhabdoid tumors: a monocentric retrospective analysis.Front Pediatr. 2025 Mar 6;13:1463510. doi: 10.3389/fped.2025.1463510. eCollection 2025. Front Pediatr. 2025. PMID: 40115317 Free PMC article.
-
DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts.Acta Neuropathol. 2023 Sep;146(3):543-545. doi: 10.1007/s00401-023-02614-9. Epub 2023 Jul 31. Acta Neuropathol. 2023. PMID: 37522896 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous